Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pfizer plots spinoff of Japanese R&D
Saved by the spinoff. Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. The company may retain an equity stake in the lab, which focuses on developing pain relievers and digestive remedies.
Apparently Pfizer's close involvement in the spun-off lab is a sticking point with the potential investors--some want it, and some think the lab would be better off if it's more independent.
- read this piece from CNNMoney
Related Articles:
Pfizer honcho details plans to boost sales. Report
Pfizer's future rests with biotech. Report
Pfizer goes public with R&D pipeline. Report
Troubled Pfizer blueprints biotech venture effort. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
